nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Rosuvastatin—atherosclerosis	0.0713	0.211	CbGbCtD
Pimecrolimus—CYP3A4—Ezetimibe—atherosclerosis	0.0713	0.211	CbGbCtD
Pimecrolimus—CYP3A4—Simvastatin—atherosclerosis	0.0663	0.196	CbGbCtD
Pimecrolimus—CYP3A4—Pravastatin—atherosclerosis	0.0648	0.192	CbGbCtD
Pimecrolimus—CYP3A4—Lovastatin—atherosclerosis	0.0648	0.192	CbGbCtD
Pimecrolimus—MTOR—leg—atherosclerosis	0.028	0.225	CbGeAlD
Pimecrolimus—MTOR—hindlimb—atherosclerosis	0.025	0.201	CbGeAlD
Pimecrolimus—Neoplasm skin—Niacin—atherosclerosis	0.0235	0.0842	CcSEcCtD
Pimecrolimus—MTOR—appendage—atherosclerosis	0.0214	0.173	CbGeAlD
Pimecrolimus—MTOR—blood vessel—atherosclerosis	0.0119	0.0961	CbGeAlD
Pimecrolimus—Tracheobronchitis—Pravastatin—atherosclerosis	0.00881	0.0316	CcSEcCtD
Pimecrolimus—MTOR—connective tissue—atherosclerosis	0.00612	0.0493	CbGeAlD
Pimecrolimus—Application site reaction—Niacin—atherosclerosis	0.00576	0.0207	CcSEcCtD
Pimecrolimus—Furuncle—Niacin—atherosclerosis	0.00551	0.0198	CcSEcCtD
Pimecrolimus—FKBP1A—connective tissue—atherosclerosis	0.00551	0.0443	CbGeAlD
Pimecrolimus—MTOR—cardiovascular system—atherosclerosis	0.00533	0.0429	CbGeAlD
Pimecrolimus—FKBP1A—cardiovascular system—atherosclerosis	0.00479	0.0386	CbGeAlD
Pimecrolimus—MTOR—adipose tissue—atherosclerosis	0.0047	0.0378	CbGeAlD
Pimecrolimus—Skin hyperpigmentation—Niacin—atherosclerosis	0.00454	0.0163	CcSEcCtD
Pimecrolimus—FKBP1A—adipose tissue—atherosclerosis	0.00422	0.034	CbGeAlD
Pimecrolimus—Eye irritation—Lovastatin—atherosclerosis	0.00369	0.0132	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00361	0.013	CcSEcCtD
Pimecrolimus—Viral infection—Ezetimibe—atherosclerosis	0.00342	0.0123	CcSEcCtD
Pimecrolimus—Bone disorder—Ezetimibe—atherosclerosis	0.00342	0.0123	CcSEcCtD
Pimecrolimus—MTOR—liver—atherosclerosis	0.00329	0.0265	CbGeAlD
Pimecrolimus—Gastroenteritis—Rosuvastatin—atherosclerosis	0.00304	0.0109	CcSEcCtD
Pimecrolimus—Skin discolouration—Niacin—atherosclerosis	0.00299	0.0107	CcSEcCtD
Pimecrolimus—Bone disorder—Niacin—atherosclerosis	0.00299	0.0107	CcSEcCtD
Pimecrolimus—FKBP1A—liver—atherosclerosis	0.00296	0.0238	CbGeAlD
Pimecrolimus—Viral infection—Pravastatin—atherosclerosis	0.00295	0.0106	CcSEcCtD
Pimecrolimus—Skin exfoliation—Niacin—atherosclerosis	0.00258	0.00927	CcSEcCtD
Pimecrolimus—Breast disorder—Rosuvastatin—atherosclerosis	0.00244	0.00875	CcSEcCtD
Pimecrolimus—Swelling—Simvastatin—atherosclerosis	0.00242	0.0087	CcSEcCtD
Pimecrolimus—Influenza—Rosuvastatin—atherosclerosis	0.00233	0.00837	CcSEcCtD
Pimecrolimus—Bronchitis—Rosuvastatin—atherosclerosis	0.00224	0.00805	CcSEcCtD
Pimecrolimus—Breast disorder—Ezetimibe—atherosclerosis	0.00202	0.00727	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Ezetimibe—atherosclerosis	0.002	0.0072	CcSEcCtD
Pimecrolimus—Influenza—Lovastatin—atherosclerosis	0.00197	0.00709	CcSEcCtD
Pimecrolimus—Sinusitis—Rosuvastatin—atherosclerosis	0.00195	0.007	CcSEcCtD
Pimecrolimus—Influenza—Ezetimibe—atherosclerosis	0.00194	0.00695	CcSEcCtD
Pimecrolimus—Face oedema—Niacin—atherosclerosis	0.00189	0.0068	CcSEcCtD
Pimecrolimus—Rhinitis—Rosuvastatin—atherosclerosis	0.00187	0.00671	CcSEcCtD
Pimecrolimus—Pharyngitis—Rosuvastatin—atherosclerosis	0.00185	0.00665	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Lovastatin—atherosclerosis	0.0018	0.00647	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.0018	0.00646	CcSEcCtD
Pimecrolimus—Bronchitis—Simvastatin—atherosclerosis	0.00178	0.00638	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00177	0.00635	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Pravastatin—atherosclerosis	0.00173	0.0062	CcSEcCtD
Pimecrolimus—Infestation NOS—Ezetimibe—atherosclerosis	0.00173	0.0062	CcSEcCtD
Pimecrolimus—Infestation—Ezetimibe—atherosclerosis	0.00173	0.0062	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00172	0.00616	CcSEcCtD
Pimecrolimus—Influenza—Niacin—atherosclerosis	0.0017	0.00609	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00169	0.00605	CcSEcCtD
Pimecrolimus—Influenza—Pravastatin—atherosclerosis	0.00167	0.006	CcSEcCtD
Pimecrolimus—Sinusitis—Lovastatin—atherosclerosis	0.00165	0.00593	CcSEcCtD
Pimecrolimus—Bronchitis—Niacin—atherosclerosis	0.00163	0.00586	CcSEcCtD
Pimecrolimus—Sinusitis—Ezetimibe—atherosclerosis	0.00162	0.00582	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00155	0.00557	CcSEcCtD
Pimecrolimus—Sinusitis—Simvastatin—atherosclerosis	0.00154	0.00555	CcSEcCtD
Pimecrolimus—Pharyngitis—Ezetimibe—atherosclerosis	0.00154	0.00552	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00152	0.00547	CcSEcCtD
Pimecrolimus—Angioedema—Rosuvastatin—atherosclerosis	0.00148	0.00533	CcSEcCtD
Pimecrolimus—Flushing—Lovastatin—atherosclerosis	0.00147	0.00527	CcSEcCtD
Pimecrolimus—Flushing—Ezetimibe—atherosclerosis	0.00144	0.00517	CcSEcCtD
Pimecrolimus—Cough—Rosuvastatin—atherosclerosis	0.00142	0.00509	CcSEcCtD
Pimecrolimus—Immune system disorder—Ezetimibe—atherosclerosis	0.0014	0.00503	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Ezetimibe—atherosclerosis	0.0014	0.00502	CcSEcCtD
Pimecrolimus—Sinusitis—Pravastatin—atherosclerosis	0.0014	0.00502	CcSEcCtD
Pimecrolimus—Arthralgia—Rosuvastatin—atherosclerosis	0.00138	0.00496	CcSEcCtD
Pimecrolimus—Flushing—Simvastatin—atherosclerosis	0.00137	0.00493	CcSEcCtD
Pimecrolimus—Rhinitis—Niacin—atherosclerosis	0.00136	0.00489	CcSEcCtD
Pimecrolimus—Erythema—Ezetimibe—atherosclerosis	0.00135	0.00485	CcSEcCtD
Pimecrolimus—Malnutrition—Ezetimibe—atherosclerosis	0.00135	0.00485	CcSEcCtD
Pimecrolimus—Rhinitis—Pravastatin—atherosclerosis	0.00134	0.00481	CcSEcCtD
Pimecrolimus—Back pain—Lovastatin—atherosclerosis	0.00133	0.00478	CcSEcCtD
Pimecrolimus—Pharyngitis—Pravastatin—atherosclerosis	0.00133	0.00476	CcSEcCtD
Pimecrolimus—Infection—Rosuvastatin—atherosclerosis	0.00132	0.00473	CcSEcCtD
Pimecrolimus—Back pain—Ezetimibe—atherosclerosis	0.00131	0.00469	CcSEcCtD
Pimecrolimus—Nervous system disorder—Rosuvastatin—atherosclerosis	0.0013	0.00467	CcSEcCtD
Pimecrolimus—Erythema—Simvastatin—atherosclerosis	0.00129	0.00462	CcSEcCtD
Pimecrolimus—Eye disorder—Niacin—atherosclerosis	0.00127	0.00456	CcSEcCtD
Pimecrolimus—Flushing—Niacin—atherosclerosis	0.00126	0.00452	CcSEcCtD
Pimecrolimus—Angioedema—Lovastatin—atherosclerosis	0.00126	0.00451	CcSEcCtD
Pimecrolimus—Flushing—Pravastatin—atherosclerosis	0.00124	0.00445	CcSEcCtD
Pimecrolimus—Angioedema—Ezetimibe—atherosclerosis	0.00123	0.00443	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00121	0.00433	CcSEcCtD
Pimecrolimus—Paraesthesia—Rosuvastatin—atherosclerosis	0.00119	0.00427	CcSEcCtD
Pimecrolimus—Malnutrition—Niacin—atherosclerosis	0.00118	0.00424	CcSEcCtD
Pimecrolimus—Erythema—Niacin—atherosclerosis	0.00118	0.00424	CcSEcCtD
Pimecrolimus—Cough—Ezetimibe—atherosclerosis	0.00118	0.00423	CcSEcCtD
Pimecrolimus—Angioedema—Simvastatin—atherosclerosis	0.00118	0.00422	CcSEcCtD
Pimecrolimus—Arthralgia—Lovastatin—atherosclerosis	0.00117	0.00421	CcSEcCtD
Pimecrolimus—Arthralgia—Ezetimibe—atherosclerosis	0.00115	0.00413	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00114	0.0041	CcSEcCtD
Pimecrolimus—Pain—Rosuvastatin—atherosclerosis	0.00113	0.00407	CcSEcCtD
Pimecrolimus—Constipation—Rosuvastatin—atherosclerosis	0.00113	0.00407	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Lovastatin—atherosclerosis	0.00112	0.00403	CcSEcCtD
Pimecrolimus—Infection—Lovastatin—atherosclerosis	0.00112	0.00401	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Ezetimibe—atherosclerosis	0.0011	0.00395	CcSEcCtD
Pimecrolimus—Arthralgia—Simvastatin—atherosclerosis	0.0011	0.00393	CcSEcCtD
Pimecrolimus—Infection—Ezetimibe—atherosclerosis	0.00109	0.00393	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00108	0.00389	CcSEcCtD
Pimecrolimus—Nervous system disorder—Ezetimibe—atherosclerosis	0.00108	0.00388	CcSEcCtD
Pimecrolimus—Angioedema—Niacin—atherosclerosis	0.00108	0.00388	CcSEcCtD
Pimecrolimus—Skin disorder—Ezetimibe—atherosclerosis	0.00107	0.00384	CcSEcCtD
Pimecrolimus—Angioedema—Pravastatin—atherosclerosis	0.00106	0.00382	CcSEcCtD
Pimecrolimus—Urticaria—Rosuvastatin—atherosclerosis	0.00105	0.00378	CcSEcCtD
Pimecrolimus—Oedema—Simvastatin—atherosclerosis	0.00105	0.00377	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Simvastatin—atherosclerosis	0.00105	0.00377	CcSEcCtD
Pimecrolimus—Abdominal pain—Rosuvastatin—atherosclerosis	0.00105	0.00376	CcSEcCtD
Pimecrolimus—Infection—Simvastatin—atherosclerosis	0.00104	0.00375	CcSEcCtD
Pimecrolimus—Cough—Niacin—atherosclerosis	0.00103	0.0037	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00102	0.00367	CcSEcCtD
Pimecrolimus—Cough—Pravastatin—atherosclerosis	0.00102	0.00365	CcSEcCtD
Pimecrolimus—Paraesthesia—Lovastatin—atherosclerosis	0.00101	0.00362	CcSEcCtD
Pimecrolimus—Arthralgia—Niacin—atherosclerosis	0.00101	0.00361	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.001	0.0036	CcSEcCtD
Pimecrolimus—Dyspnoea—Lovastatin—atherosclerosis	0.001	0.00359	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000999	0.00359	CcSEcCtD
Pimecrolimus—Arthralgia—Pravastatin—atherosclerosis	0.000991	0.00356	CcSEcCtD
Pimecrolimus—Paraesthesia—Ezetimibe—atherosclerosis	0.000989	0.00355	CcSEcCtD
Pimecrolimus—Dyspnoea—Ezetimibe—atherosclerosis	0.000982	0.00353	CcSEcCtD
Pimecrolimus—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000976	0.00351	CcSEcCtD
Pimecrolimus—CYP3A4—liver—atherosclerosis	0.000968	0.00779	CbGeAlD
Pimecrolimus—Anaphylactic shock—Niacin—atherosclerosis	0.000964	0.00346	CcSEcCtD
Pimecrolimus—Oedema—Niacin—atherosclerosis	0.000964	0.00346	CcSEcCtD
Pimecrolimus—Pain—Lovastatin—atherosclerosis	0.00096	0.00345	CcSEcCtD
Pimecrolimus—Constipation—Lovastatin—atherosclerosis	0.00096	0.00345	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000957	0.00344	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000951	0.00341	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Pravastatin—atherosclerosis	0.00095	0.00341	CcSEcCtD
Pimecrolimus—Oedema—Pravastatin—atherosclerosis	0.00095	0.00341	CcSEcCtD
Pimecrolimus—Infection—Pravastatin—atherosclerosis	0.000943	0.00339	CcSEcCtD
Pimecrolimus—Paraesthesia—Simvastatin—atherosclerosis	0.000943	0.00339	CcSEcCtD
Pimecrolimus—Pain—Ezetimibe—atherosclerosis	0.000942	0.00338	CcSEcCtD
Pimecrolimus—Constipation—Ezetimibe—atherosclerosis	0.000942	0.00338	CcSEcCtD
Pimecrolimus—Pruritus—Rosuvastatin—atherosclerosis	0.000937	0.00337	CcSEcCtD
Pimecrolimus—Skin disorder—Niacin—atherosclerosis	0.000937	0.00336	CcSEcCtD
Pimecrolimus—Dyspnoea—Simvastatin—atherosclerosis	0.000936	0.00336	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000918	0.0033	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000907	0.00326	CcSEcCtD
Pimecrolimus—Diarrhoea—Rosuvastatin—atherosclerosis	0.000907	0.00326	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000901	0.00323	CcSEcCtD
Pimecrolimus—Pain—Simvastatin—atherosclerosis	0.000898	0.00323	CcSEcCtD
Pimecrolimus—Constipation—Simvastatin—atherosclerosis	0.000898	0.00323	CcSEcCtD
Pimecrolimus—Urticaria—Lovastatin—atherosclerosis	0.000892	0.0032	CcSEcCtD
Pimecrolimus—Body temperature increased—Lovastatin—atherosclerosis	0.000888	0.00319	CcSEcCtD
Pimecrolimus—Abdominal pain—Lovastatin—atherosclerosis	0.000888	0.00319	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000879	0.00316	CcSEcCtD
Pimecrolimus—Urticaria—Ezetimibe—atherosclerosis	0.000875	0.00314	CcSEcCtD
Pimecrolimus—Body temperature increased—Ezetimibe—atherosclerosis	0.000871	0.00313	CcSEcCtD
Pimecrolimus—Abdominal pain—Ezetimibe—atherosclerosis	0.000871	0.00313	CcSEcCtD
Pimecrolimus—Paraesthesia—Niacin—atherosclerosis	0.000866	0.00311	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000865	0.00311	CcSEcCtD
Pimecrolimus—Dyspnoea—Niacin—atherosclerosis	0.00086	0.00309	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000859	0.00308	CcSEcCtD
Pimecrolimus—Paraesthesia—Pravastatin—atherosclerosis	0.000853	0.00306	CcSEcCtD
Pimecrolimus—Dyspnoea—Pravastatin—atherosclerosis	0.000847	0.00304	CcSEcCtD
Pimecrolimus—Rash—Rosuvastatin—atherosclerosis	0.000835	0.003	CcSEcCtD
Pimecrolimus—Dermatitis—Rosuvastatin—atherosclerosis	0.000835	0.003	CcSEcCtD
Pimecrolimus—Urticaria—Simvastatin—atherosclerosis	0.000834	0.003	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Niacin—atherosclerosis	0.000833	0.00299	CcSEcCtD
Pimecrolimus—Abdominal pain—Simvastatin—atherosclerosis	0.00083	0.00298	CcSEcCtD
Pimecrolimus—Body temperature increased—Simvastatin—atherosclerosis	0.00083	0.00298	CcSEcCtD
Pimecrolimus—Headache—Rosuvastatin—atherosclerosis	0.00083	0.00298	CcSEcCtD
Pimecrolimus—Hypersensitivity—Lovastatin—atherosclerosis	0.000827	0.00297	CcSEcCtD
Pimecrolimus—Pain—Niacin—atherosclerosis	0.000825	0.00296	CcSEcCtD
Pimecrolimus—Pain—Pravastatin—atherosclerosis	0.000812	0.00292	CcSEcCtD
Pimecrolimus—Constipation—Pravastatin—atherosclerosis	0.000812	0.00292	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ezetimibe—atherosclerosis	0.000811	0.00291	CcSEcCtD
Pimecrolimus—Pruritus—Lovastatin—atherosclerosis	0.000794	0.00285	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Niacin—atherosclerosis	0.000789	0.00283	CcSEcCtD
Pimecrolimus—Nausea—Rosuvastatin—atherosclerosis	0.000787	0.00283	CcSEcCtD
Pimecrolimus—Pruritus—Ezetimibe—atherosclerosis	0.000779	0.0028	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000776	0.00279	CcSEcCtD
Pimecrolimus—Hypersensitivity—Simvastatin—atherosclerosis	0.000774	0.00278	CcSEcCtD
Pimecrolimus—Diarrhoea—Lovastatin—atherosclerosis	0.000768	0.00276	CcSEcCtD
Pimecrolimus—Urticaria—Niacin—atherosclerosis	0.000766	0.00275	CcSEcCtD
Pimecrolimus—Abdominal pain—Niacin—atherosclerosis	0.000762	0.00274	CcSEcCtD
Pimecrolimus—Body temperature increased—Niacin—atherosclerosis	0.000762	0.00274	CcSEcCtD
Pimecrolimus—Urticaria—Pravastatin—atherosclerosis	0.000754	0.00271	CcSEcCtD
Pimecrolimus—Diarrhoea—Ezetimibe—atherosclerosis	0.000754	0.00271	CcSEcCtD
Pimecrolimus—Abdominal pain—Pravastatin—atherosclerosis	0.000751	0.0027	CcSEcCtD
Pimecrolimus—Body temperature increased—Pravastatin—atherosclerosis	0.000751	0.0027	CcSEcCtD
Pimecrolimus—Pruritus—Simvastatin—atherosclerosis	0.000743	0.00267	CcSEcCtD
Pimecrolimus—Diarrhoea—Simvastatin—atherosclerosis	0.000719	0.00258	CcSEcCtD
Pimecrolimus—Vomiting—Lovastatin—atherosclerosis	0.000714	0.00256	CcSEcCtD
Pimecrolimus—Hypersensitivity—Niacin—atherosclerosis	0.000711	0.00255	CcSEcCtD
Pimecrolimus—Rash—Lovastatin—atherosclerosis	0.000708	0.00254	CcSEcCtD
Pimecrolimus—Dermatitis—Lovastatin—atherosclerosis	0.000707	0.00254	CcSEcCtD
Pimecrolimus—Headache—Lovastatin—atherosclerosis	0.000703	0.00253	CcSEcCtD
Pimecrolimus—Vomiting—Ezetimibe—atherosclerosis	0.0007	0.00251	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pravastatin—atherosclerosis	0.0007	0.00251	CcSEcCtD
Pimecrolimus—Rash—Ezetimibe—atherosclerosis	0.000694	0.00249	CcSEcCtD
Pimecrolimus—Dermatitis—Ezetimibe—atherosclerosis	0.000694	0.00249	CcSEcCtD
Pimecrolimus—Headache—Ezetimibe—atherosclerosis	0.00069	0.00248	CcSEcCtD
Pimecrolimus—Pruritus—Niacin—atherosclerosis	0.000682	0.00245	CcSEcCtD
Pimecrolimus—Pruritus—Pravastatin—atherosclerosis	0.000672	0.00241	CcSEcCtD
Pimecrolimus—Vomiting—Simvastatin—atherosclerosis	0.000668	0.0024	CcSEcCtD
Pimecrolimus—Nausea—Lovastatin—atherosclerosis	0.000667	0.00239	CcSEcCtD
Pimecrolimus—Rash—Simvastatin—atherosclerosis	0.000662	0.00238	CcSEcCtD
Pimecrolimus—Dermatitis—Simvastatin—atherosclerosis	0.000662	0.00238	CcSEcCtD
Pimecrolimus—Diarrhoea—Niacin—atherosclerosis	0.00066	0.00237	CcSEcCtD
Pimecrolimus—Headache—Simvastatin—atherosclerosis	0.000658	0.00236	CcSEcCtD
Pimecrolimus—Nausea—Ezetimibe—atherosclerosis	0.000654	0.00235	CcSEcCtD
Pimecrolimus—Diarrhoea—Pravastatin—atherosclerosis	0.00065	0.00233	CcSEcCtD
Pimecrolimus—Nausea—Simvastatin—atherosclerosis	0.000624	0.00224	CcSEcCtD
Pimecrolimus—Vomiting—Niacin—atherosclerosis	0.000613	0.0022	CcSEcCtD
Pimecrolimus—Rash—Niacin—atherosclerosis	0.000608	0.00218	CcSEcCtD
Pimecrolimus—Dermatitis—Niacin—atherosclerosis	0.000607	0.00218	CcSEcCtD
Pimecrolimus—Headache—Niacin—atherosclerosis	0.000604	0.00217	CcSEcCtD
Pimecrolimus—Vomiting—Pravastatin—atherosclerosis	0.000604	0.00217	CcSEcCtD
Pimecrolimus—Rash—Pravastatin—atherosclerosis	0.000599	0.00215	CcSEcCtD
Pimecrolimus—Dermatitis—Pravastatin—atherosclerosis	0.000598	0.00215	CcSEcCtD
Pimecrolimus—Headache—Pravastatin—atherosclerosis	0.000595	0.00214	CcSEcCtD
Pimecrolimus—Nausea—Niacin—atherosclerosis	0.000573	0.00206	CcSEcCtD
Pimecrolimus—Nausea—Pravastatin—atherosclerosis	0.000564	0.00203	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CCL4—atherosclerosis	0.000112	0.000431	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LDLR—atherosclerosis	0.000112	0.000431	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—atherosclerosis	0.000111	0.00043	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—atherosclerosis	0.000111	0.000428	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—atherosclerosis	0.00011	0.000426	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—atherosclerosis	0.00011	0.000426	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK8—atherosclerosis	0.00011	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CRP—atherosclerosis	0.00011	0.000424	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—atherosclerosis	0.00011	0.000424	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—atherosclerosis	0.000109	0.000422	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—atherosclerosis	0.000108	0.000419	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—atherosclerosis	0.000108	0.000418	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PDGFB—atherosclerosis	0.000108	0.000417	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HSPA1B—atherosclerosis	0.000108	0.000416	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—atherosclerosis	0.000108	0.000415	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PDGFB—atherosclerosis	0.000107	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—atherosclerosis	0.000107	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CCR2—atherosclerosis	0.000107	0.000412	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CYBA—atherosclerosis	0.000106	0.00041	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—atherosclerosis	0.000105	0.000407	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KNG1—atherosclerosis	0.000105	0.000405	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOA2—atherosclerosis	0.000104	0.000403	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NCF1—atherosclerosis	0.000104	0.000403	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGTR1—atherosclerosis	0.000104	0.000403	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—atherosclerosis	0.000103	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—atherosclerosis	0.000103	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—atherosclerosis	0.000103	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—atherosclerosis	0.000103	0.000399	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—atherosclerosis	0.000103	0.000397	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—atherosclerosis	0.000103	0.000397	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK3—atherosclerosis	0.000103	0.000396	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—atherosclerosis	0.000102	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—atherosclerosis	0.000102	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—atherosclerosis	0.000102	0.000395	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CAV1—atherosclerosis	0.000102	0.000393	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—atherosclerosis	0.000102	0.000393	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PLG—atherosclerosis	0.000102	0.000393	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOA1—atherosclerosis	0.000102	0.000392	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—atherosclerosis	0.000101	0.000392	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—atherosclerosis	0.000101	0.000391	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—atherosclerosis	0.000101	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—atherosclerosis	0.000101	0.000389	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—atherosclerosis	9.97e-05	0.000385	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—UTS2—atherosclerosis	9.95e-05	0.000385	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40—atherosclerosis	9.92e-05	0.000383	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR2—atherosclerosis	9.92e-05	0.000383	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CYBA—atherosclerosis	9.81e-05	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ICAM1—atherosclerosis	9.69e-05	0.000374	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SOCS3—atherosclerosis	9.63e-05	0.000372	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK3—atherosclerosis	9.61e-05	0.000372	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PARP1—atherosclerosis	9.6e-05	0.000371	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS2—atherosclerosis	9.57e-05	0.00037	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CX3CR1—atherosclerosis	9.54e-05	0.000369	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASR—atherosclerosis	9.54e-05	0.000369	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—atherosclerosis	9.52e-05	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—atherosclerosis	9.52e-05	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—atherosclerosis	9.52e-05	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—atherosclerosis	9.43e-05	0.000365	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CX3CL1—atherosclerosis	9.36e-05	0.000362	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—atherosclerosis	9.35e-05	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—atherosclerosis	9.31e-05	0.00036	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP3—atherosclerosis	9.3e-05	0.000359	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF2—atherosclerosis	9.26e-05	0.000358	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—atherosclerosis	9.14e-05	0.000353	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	9.12e-05	0.000352	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	8.99e-05	0.000347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOB—atherosclerosis	8.99e-05	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD14—atherosclerosis	8.94e-05	0.000346	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR2—atherosclerosis	8.87e-05	0.000343	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EDN1—atherosclerosis	8.84e-05	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—atherosclerosis	8.81e-05	0.00034	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL5—atherosclerosis	8.77e-05	0.000339	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—INS—atherosclerosis	8.77e-05	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—VCAM1—atherosclerosis	8.63e-05	0.000333	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LPL—atherosclerosis	8.58e-05	0.000332	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—atherosclerosis	8.43e-05	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SOCS3—atherosclerosis	8.37e-05	0.000324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRKCG—atherosclerosis	8.34e-05	0.000322	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SPP1—atherosclerosis	8.13e-05	0.000314	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SERPINE1—atherosclerosis	8.06e-05	0.000311	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VWF—atherosclerosis	7.91e-05	0.000306	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOC3—atherosclerosis	7.86e-05	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LDLR—atherosclerosis	7.81e-05	0.000302	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—atherosclerosis	7.69e-05	0.000297	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—atherosclerosis	7.63e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL3—atherosclerosis	7.63e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—atherosclerosis	7.6e-05	0.000294	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFB—atherosclerosis	7.52e-05	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—atherosclerosis	7.49e-05	0.00029	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGT—atherosclerosis	7.34e-05	0.000284	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AGER—atherosclerosis	7.33e-05	0.000283	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCF1—atherosclerosis	7.31e-05	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRKCG—atherosclerosis	7.26e-05	0.00028	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOB—atherosclerosis	7.22e-05	0.000279	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—atherosclerosis	7.19e-05	0.000278	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LEP—atherosclerosis	7.19e-05	0.000278	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CAV1—atherosclerosis	7.13e-05	0.000275	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOA1—atherosclerosis	7.11e-05	0.000275	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD36—atherosclerosis	7.09e-05	0.000274	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—atherosclerosis	7.04e-05	0.000272	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—atherosclerosis	7.03e-05	0.000272	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR2—atherosclerosis	6.9e-05	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDNRA—atherosclerosis	6.9e-05	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LPL—atherosclerosis	6.89e-05	0.000266	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CYBA—atherosclerosis	6.87e-05	0.000265	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ESR1—atherosclerosis	6.87e-05	0.000265	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—F2—atherosclerosis	6.78e-05	0.000262	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLAT—atherosclerosis	6.72e-05	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GHRL—atherosclerosis	6.72e-05	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PARP1—atherosclerosis	6.72e-05	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PRKCG—atherosclerosis	6.7e-05	0.000259	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFB—atherosclerosis	6.54e-05	0.000253	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—atherosclerosis	6.49e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—atherosclerosis	6.48e-05	0.000251	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	6.46e-05	0.00025	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—atherosclerosis	6.39e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKB1—atherosclerosis	6.39e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK8—atherosclerosis	6.28e-05	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—atherosclerosis	6.2e-05	0.00024	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INS—atherosclerosis	6.14e-05	0.000237	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NFKB1—atherosclerosis	6.13e-05	0.000237	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—atherosclerosis	6.13e-05	0.000237	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLTP—atherosclerosis	6.08e-05	0.000235	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—atherosclerosis	6.04e-05	0.000234	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFB—atherosclerosis	6.04e-05	0.000233	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—atherosclerosis	5.94e-05	0.00023	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KNG1—atherosclerosis	5.9e-05	0.000228	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—atherosclerosis	5.88e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGTR1—atherosclerosis	5.87e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—atherosclerosis	5.78e-05	0.000223	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—atherosclerosis	5.72e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLG—atherosclerosis	5.72e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOA1—atherosclerosis	5.71e-05	0.000221	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SERPINE1—atherosclerosis	5.64e-05	0.000218	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—atherosclerosis	5.49e-05	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK3—atherosclerosis	5.48e-05	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS3—atherosclerosis	5.41e-05	0.000209	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—atherosclerosis	5.39e-05	0.000208	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—atherosclerosis	5.38e-05	0.000208	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LTA4H—atherosclerosis	5.27e-05	0.000204	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG8—atherosclerosis	5.27e-05	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK3—atherosclerosis	5.24e-05	0.000203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP3—atherosclerosis	5.23e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF2—atherosclerosis	5.21e-05	0.000201	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—atherosclerosis	5.09e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOB—atherosclerosis	5.05e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—atherosclerosis	4.97e-05	0.000192	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL5—atherosclerosis	4.93e-05	0.000191	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—atherosclerosis	4.93e-05	0.000191	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LPL—atherosclerosis	4.83e-05	0.000186	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—atherosclerosis	4.78e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCG—atherosclerosis	4.69e-05	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—atherosclerosis	4.57e-05	0.000177	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—atherosclerosis	4.53e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—atherosclerosis	4.47e-05	0.000173	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—atherosclerosis	4.33e-05	0.000167	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—atherosclerosis	4.32e-05	0.000167	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKB1—atherosclerosis	4.28e-05	0.000165	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFB—atherosclerosis	4.23e-05	0.000163	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK8—atherosclerosis	4.2e-05	0.000162	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG1—atherosclerosis	4.17e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGT—atherosclerosis	4.13e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—atherosclerosis	4.04e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—atherosclerosis	4.04e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—atherosclerosis	4.01e-05	0.000155	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—atherosclerosis	4.01e-05	0.000155	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOA1—atherosclerosis	4e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—atherosclerosis	3.99e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—atherosclerosis	3.96e-05	0.000153	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FABP4—atherosclerosis	3.92e-05	0.000151	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LCAT—atherosclerosis	3.92e-05	0.000151	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—atherosclerosis	3.88e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—atherosclerosis	3.86e-05	0.000149	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA4—atherosclerosis	3.84e-05	0.000149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—atherosclerosis	3.84e-05	0.000149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—atherosclerosis	3.83e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—F2—atherosclerosis	3.81e-05	0.000147	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP7A1—atherosclerosis	3.78e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKB1—atherosclerosis	3.72e-05	0.000144	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—atherosclerosis	3.7e-05	0.000143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—atherosclerosis	3.67e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK8—atherosclerosis	3.66e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—atherosclerosis	3.65e-05	0.000141	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—atherosclerosis	3.56e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—atherosclerosis	3.55e-05	0.000137	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—atherosclerosis	3.54e-05	0.000137	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3.49e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—atherosclerosis	3.46e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—atherosclerosis	3.4e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—atherosclerosis	3.34e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—atherosclerosis	3.34e-05	0.000129	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA2—atherosclerosis	3.31e-05	0.000128	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3.31e-05	0.000128	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3.31e-05	0.000128	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALOX15—atherosclerosis	3.31e-05	0.000128	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG5—atherosclerosis	3.27e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—atherosclerosis	3.19e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—atherosclerosis	3.17e-05	0.000123	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPA—atherosclerosis	3.16e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—atherosclerosis	3.09e-05	0.000119	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BGN—atherosclerosis	3.06e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—atherosclerosis	3.03e-05	0.000117	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA5—atherosclerosis	3.03e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—atherosclerosis	2.95e-05	0.000114	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.91e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—atherosclerosis	2.86e-05	0.000111	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.81e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—atherosclerosis	2.69e-05	0.000104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—atherosclerosis	2.68e-05	0.000104	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.52e-05	9.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LIPC—atherosclerosis	2.51e-05	9.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOC3—atherosclerosis	2.49e-05	9.63e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LDLR—atherosclerosis	2.48e-05	9.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—atherosclerosis	2.48e-05	9.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—atherosclerosis	2.43e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CETP—atherosclerosis	2.42e-05	9.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKB1—atherosclerosis	2.41e-05	9.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK8—atherosclerosis	2.36e-05	9.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—atherosclerosis	2.34e-05	9.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.32e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.19e-05	8.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—atherosclerosis	2.18e-05	8.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—atherosclerosis	2.16e-05	8.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—atherosclerosis	2.16e-05	8.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—atherosclerosis	2.15e-05	8.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—atherosclerosis	2.07e-05	7.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—atherosclerosis	2e-05	7.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—atherosclerosis	1.99e-05	7.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.95e-05	7.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.67e-05	6.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOB—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.56e-05	6.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPL—atherosclerosis	1.53e-05	5.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—atherosclerosis	1.51e-05	5.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—atherosclerosis	1.49e-05	5.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD36—atherosclerosis	1.45e-05	5.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—atherosclerosis	1.39e-05	5.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.38e-05	5.32e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARA—atherosclerosis	1.35e-05	5.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGT—atherosclerosis	1.31e-05	5.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—atherosclerosis	1.28e-05	4.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—atherosclerosis	1.27e-05	4.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA1—atherosclerosis	1.27e-05	4.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.16e-05	4.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—atherosclerosis	1.12e-05	4.32e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—atherosclerosis	1.1e-05	4.23e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—atherosclerosis	1e-05	3.88e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—atherosclerosis	9.61e-06	3.71e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—atherosclerosis	8.79e-06	3.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—atherosclerosis	4.42e-06	1.71e-05	CbGpPWpGaD
